The gold standard for clinical evidence for efficacy is a placebo-controlled, double-blind clinical trial. Immunotec’s present research activities therefore focus on controlled clinical trials in cooperation with various clinical partners in Montreal and other clinical centers in Canada and the U.S.A. The recently published study on the effects of a research formulation of Immunocal on lung cancer patients (Tozer et al. Antioxidants & Redox Signaling, 10:2, 395-402, 2008) is an example. This trial has shown quite impressive results with regard to the health benefits of this Immunocal formulation in the nutrition of seriously ill advanced lung cancer patients. Other clinical studies showing the efficacy of Immunocal have been performed and published by several clinical centers.